Clinical trials in Durham, NC

240 recruiting studies have a site in or near Durham, NC, North Carolina.

Top conditions here

All conditions

Showing 40 of 240 studies

RecruitingPhase 3NCT04047628

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Durham, NC · +22 more sites

RecruitingPhase 1NCT07103018

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Sponsor: K36 Therapeutics, Inc.

Durham, NC · +12 more sites

RecruitingPhase 3NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Charlotte, NC · Durham, NC · Fayetteville, NC · +71 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Chapel Hill, NC · Durham, NC · Greenville, NC · +452 more sites

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Chapel Hill, NC · Charlotte, NC · Durham, NC · +37 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Asheboro, NC · +1147 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Chapel Hill, NC · Charlotte, NC · Durham, NC · +112 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Cary, NC · Durham, NC · +278 more sites

RecruitingPhase 3NCT07190209

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Sponsor: Sanofi

Durham, NC · Hickory, NC · Morrisville, NC · +72 more sites

RecruitingPhase 3NCT07404865

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Sponsor: Vor Biopharma

Charlotte, NC · Durham, NC · +45 more sites

RecruitingPhase 3NCT07525206

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Sponsor: AbbVie

Durham, NC · +17 more sites

RecruitingNot applicableNCT07783152

Lupus Nephritis Care Pathway

Sponsor: Duke University

Durham, NC

RecruitingPhase not listedNCT04302272

STRIVE Post-Market Registry Study

Sponsor: Olympus Corporation of the Americas

Durham, NC · +15 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Charlotte, NC · Durham, NC · +172 more sites

RecruitingPhase 1NCT06179069

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Durham, NC · +10 more sites

RecruitingPhase not listedNCT06297291

Global Paradise System US Post Approval Study

Sponsor: ReCor Medical, Inc.

Chapel Hill, NC · Durham, NC · Raleigh, NC · +43 more sites

RecruitingNot applicableNCT06627764

SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families

Sponsor: Duke University

Durham, NC

RecruitingPhase 3NCT07391774

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Sponsor: National Cancer Institute (NCI)

Cary, NC · Clinton, NC · Durham, NC · +200 more sites

RecruitingPhase 1NCT06120283

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sponsor: BeOne Medicines

Durham, NC · +8 more sites

RecruitingPhase 3NCT07181109

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Sponsor: Alnylam Pharmaceuticals

Durham, NC · Greenville, NC · High Point, NC · +270 more sites

RecruitingPhase 1 / Phase 2NCT07226986

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Sponsor: Novartis Pharmaceuticals

Durham, NC · +3 more sites

RecruitingPhase not listedNCT07612878

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Sponsor: Sanofi

Durham, NC · +6 more sites

RecruitingPhase 2NCT06188923

A New Intervention to Improve Function in Veterans With Anxiety and Depression

Sponsor: VA Office of Research and Development

Durham, NC

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Chapel Hill, NC · Charlotte, NC · Durham, NC · +222 more sites

RecruitingPhase 3NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Sponsor: Pfizer

Cary, NC · Durham, NC · +124 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Durham, NC · +20 more sites

RecruitingPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Sponsor: AstraZeneca

Asheville, NC · Chapel Hill, NC · Charlotte, NC · +163 more sites

RecruitingPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor: AstraZeneca

Charlotte, NC · Durham, NC · +118 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Durham, NC · +19 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Charlotte, NC · Durham, NC · Greenville, NC · +132 more sites

RecruitingPhase 3NCT06736574

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Sponsor: Cytokinetics

Cary, NC · Chapel Hill, NC · Durham, NC · +85 more sites

RecruitingNot applicableNCT06898515

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Sponsor: Reprieve Cardiovascular, Inc

Durham, NC · Greensboro, NC · Winston-Salem, NC · +32 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Durham, NC · Pinehurst, NC · +51 more sites

RecruitingNot applicableNCT06965504

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

Sponsor: Abiomed Inc.

Charlotte, NC · Durham, NC · Winston-Salem, NC · +14 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Chapel Hill, NC · Durham, NC · +42 more sites

RecruitingPhase 3NCT07128199

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Sponsor: Taiho Oncology, Inc.

Charlotte, NC · Durham, NC · +28 more sites

RecruitingPhase 3NCT07179380

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Sponsor: Insmed Incorporated

Chapel Hill, NC · Durham, NC · +17 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

Durham, NC · +21 more sites

RecruitingPhase 2NCT07023289

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Sponsor: AbbVie

Durham, NC · +21 more sites

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

Durham, NC · +18 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.